Loading company…
Nectar Lifesciences provides a data-informed platform for personalized allergy care.
Founded in 2021 and based in the US, Nectar Lifesciences is developing a personalized allergy healthcare platform informed by data and clinical research. In March 2022, the company raised USD 8 million in seed funding co-led by Juxtapose and Obvious Ventures to continue developing its allergy solutions ahead of a planned nationwide launch.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in